| Name | Title | Contact Details |
|---|
XIFIN, Inc. is an innovative software and services company dedicated to optimizing the economics of healthcare. The company`s cloud-based technology and business intelligence platform links healthcare stakeholders in the delivery and reimbursement of care, optimizing both business and patient outcomes and providing informed, streamlined diagnostic and business decision-making.
Carrot is a complete global fertility solution for today`s modern employers and payers, providing flexible financial coverage and expert care navigation across the U.S. and 50+ countries. Get a quick demo and briefing about how modern companies are using Carrot to drive down healthcare costs, attract and retain top talent, and build cultures of inclusion.
Healthcare Interactive, Inc. (HCIactive) is dedicated to revolutionizing the administration and delivery of healthcare. Through our patented, integrative technology and supplemental ancillary services, we afford clients the freedom, control and energy to provide high-performance plan solutions that mitigate risk and improve member outcomes. Disparate plan functions, such as enrollment and eligibility, incentive management and population health are seamlessly conducted through our single-source, cloud-based platform. The outcome: greater operational efficiency, actionable performance data, increased member participation, and overall reduced healthcare costs. Founded in 2006, HCIactive is the progressive leader in delivering integrated, health plan solutions to TPA`s, brokers, health systems, providers and their customers. Our executive leadership team is comprised of seasoned professionals who have established successful track-records in the healthcare industry with over 85 years of combined experience.
Care Access Health Plan is a Hallandale, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kolltan Pharmaceuticals is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.